comparemela.com

Latest Breaking News On - Japan new drug application - Page 1 : comparemela.com

Esperion Reports First Quarter 2024 Financial Results

– Q1 Total Revenue Grew 467% Y/Y to $137.7 Million, Reflecting Strong Growth Globally – – Q1 U.S. Net Product Revenue Grew 46% Y/Y to $24.8 Million – – Q1 Retail Prescription Equivalents.

Netherlands
Thailand
Japan
Czech-republic
Tiffany-aldrich
Daiichi-sankyo-europe
Sheldon-koenig
Esperion-therapeutics-inc
European-commission-decision-for-expanded-labels
National-health-insurance
Exchange-commission
European-commission

Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript

Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript May 2, 2024 Genmab A/S reports earnings inline with expectations. Reported EPS is $0.16 EPS, expectations were $0.16. Genmab A/S isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, and welcome to […]

Japan
Anthony-pagano
Anthony
Japan-new-drug-application
Genmab
Follicular-lymphoma
Anthony-mancini
Japan

Genmab A/S : Interim Report for the First Quarter of 2024

Genmab Announces Financial Results for the First Quarter of 2024 May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended.

Copenhagen
Køavn
Denmark
China
Japan
Valby
Hovedstaden
Japanese
Genmab-duobody
Tivdak-genmab
Andrew-carlsen
Informationfor-tivdak

Esperion Reports Fourth Quarter and Full Year 2023 Financial Results

– FY23 U.S. Net Product Revenue Grew 40% Y/Y to $78.3 Million; FY23 Total Revenue Grew 54% Y/Y to $116.3 Million – – Q4 U.S. Net Product Revenue Grew 39% Y/Y to $20.8 Million; Q4 Total.

Spain
Australia
Hong-kong
Canada
Japan
United-states
Czech-republic
American
Alexis-callahan
Daiichi-sankyo-asia
Daiichi-sankyo-europe
Sheldon-koenig

vimarsana © 2020. All Rights Reserved.